https://www.selleckchem.com/pr....oducts/leukadherin-1
he safety profile of the two treatments; both were associated with lower risks of revision surgery than previously reported. Cite this article Bone Joint J 2021;103-B(2)256-263.Two new sucrose derivatives, named as cannadica A (1) and cannadica B (2), and eight known compounds, 6'-O-acetyl-3-O-(E)-p-coumaroylsucrose (3), heterophylloside C (4), 6'-O-vanilloylarbutin (5), isotachioside (6), 2,6-dimethoxy-p-hydroquinone 1-O-β-D-glucopyranoside (7), 3,5-dimethoxy-p-hydroquinone 1-O-β-D-glucopyranoside (8), benzyl glucoside (9), and 3
Like
Comment
Share
